A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Public ClinicalTrials.gov record NCT04296890. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All participants will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.
Study identification
- NCT ID
- NCT04296890
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 106 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2020 (Actual)
- Primary completion
- Nov 16, 2021 (Actual)
- Completion
- Nov 16, 2022 (Actual)
- Last update posted
- Aug 7, 2024
2020 – 2022
United States locations
- U.S. sites
- 34
- U.S. states
- 20
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Phoenix | Arizona | 85016 | — |
| City of Hope Medical Center | Duarte | California | 91010 | — |
| California Cancer Associates (cCARE) | Fresno | California | 93720 | — |
| Stanford School of Medicine | Palo Alto | California | 94394 | — |
| California Pacific Medical Center Research Institute | San Francisco | California | 94109 | — |
| Rocky Mountain Cancer Centers | Littleton | Colorado | 80120 | — |
| Sarasota Memorial Health Care System | Sarasota | Florida | 34239 | — |
| Florida Cancer Specialists Panhandle | Tallahassee | Florida | 32308 | — |
| University of South Florida | Tampa | Florida | 33606 | — |
| Florida Cancer Specialists Research | West Palm Beach | Florida | 33401 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Hinsdale Hospital | Hinsdale | Illinois | 60521 | — |
| St. Vincent Gynecologic Oncology | Indianapolis | Indiana | 46260 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Women's Cancer Center | Covington | Louisiana | 70433 | — |
| Maryland Oncology Hematology, P.A. | Rockville | Maryland | 20850 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Midwest Oncology Associates/Sarah Cannon | Kansas City | Missouri | 64132 | — |
| Center of Hope at Renown Medical Center | Reno | Nevada | 89502 | — |
| Holy Name Medical Center | Teaneck | New Jersey | 07666 | — |
| Mount Sinai Health System | New York | New York | 10029 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Sarah Cannon Research Institute / Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Austin Central | Austin | Texas | 78731 | — |
| Texas Oncology, P.A. - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| Texas Oncology, P.A. - McAllen | McAllen | Texas | 78503 | — |
| Texas Oncology, P.A. - Sugar Land | Sugar Land | Texas | 77479 | — |
| USOR: Texas Oncology - The Woodlands, Gynecologic Oncology | The Woodlands | Texas | 77380 | — |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53792 | — |
| Froedtert and the Medical College of Wisconsin Department of Obstetrics & Gynecology | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04296890, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04296890 live on ClinicalTrials.gov.